EDESA BIOTECH, INC. Government Assistance Nonoperating Income
EDESA BIOTECH, INC. (EDSA) reported Government Assistance Nonoperating Income of $107.37 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:GovernmentAssistanceNonoperatingIncome · last filed 2026-08-13
- EDESA BIOTECH, INC. government assistance nonoperating income for the quarter ending 2026-06-30 was $107.37K, a 41.42% decline year-over-year.
- EDESA BIOTECH, INC. government assistance nonoperating income for the quarter ending 2026-03-31 was $66.23K, a 26.71% increase year-over-year.
- EDESA BIOTECH, INC. government assistance nonoperating income for the quarter ending 2025-12-31 was $102.42K, a 65.99% decline year-over-year.
- EDESA BIOTECH, INC. government assistance nonoperating income for the quarter ending 2025-09-30 was $247.15K, a 564.11% increase year-over-year.
- EDESA BIOTECH, INC. government assistance nonoperating income for fiscal 2025 was $783.89K, a 12.26% increase from fiscal 2024.
- EDESA BIOTECH, INC. government assistance nonoperating income for fiscal 2024 was $698.28K, a 20.18% increase from fiscal 2023.
- EDESA BIOTECH, INC. government assistance nonoperating income for fiscal 2023 was $581.04K.
| Period end | Government Assistance Nonoperating Income 3 month | Government Assistance Nonoperating Income 6 month | Government Assistance Nonoperating Income 9 month | Government Assistance Nonoperating Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $107.37K 10-Q · filed 2026-08-13 | $173.60K derived: sum of 2 quarters · filed 2026-08-13 | $276.02K 10-Q · filed 2026-08-13 | $523.17K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $66.23K 10-Q · filed 2026-05-14 | $168.65K 10-Q · filed 2026-05-14 | $415.80K derived: sum of 3 quarters · filed 2026-05-14 | $599.08K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $102.42K 10-Q · filed 2026-02-13 | $349.57K derived: sum of 2 quarters · filed 2026-02-13 | $532.86K derived: sum of 3 quarters · filed 2026-08-13 | $585.12K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | $247.15K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | $430.43K derived: sum of 2 quarters · filed 2026-08-13 | $482.70K derived: sum of 3 quarters · filed 2026-08-13 | $783.89K 10-K · filed 2025-12-12 |
| 2025-06-30 | $183.28K 10-Q · filed 2026-08-13 | $235.55K derived: sum of 2 quarters · filed 2026-08-13 | $536.74K 10-Q · filed 2026-08-13 | $573.96K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $52.27K 10-Q · filed 2026-05-14 | $353.46K 10-Q · filed 2026-05-14 | $390.68K derived: sum of 3 quarters · filed 2026-05-14 | $626.90K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $301.19K 10-Q · filed 2026-02-13 | $338.41K derived: sum of 2 quarters · filed 2026-02-13 | $574.64K derived: sum of 3 quarters · filed 2026-02-13 | $878.64K derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | $37.22K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | $273.44K derived: sum of 2 quarters · filed 2025-12-12 | $577.44K derived: sum of 3 quarters · filed 2025-12-12 | $698.28K 10-K · filed 2025-12-12 |
| 2024-06-30 | $236.23K 10-Q · filed 2025-08-08 | $540.23K derived: sum of 2 quarters · filed 2025-08-08 | $661.06K 10-Q · filed 2025-08-08 | $1.24M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $304.00K 10-Q · filed 2025-05-14 | $424.84K 10-Q · filed 2025-05-14 | $1.01M derived: sum of 3 quarters · filed 2025-05-14 | $1.01M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $120.83K 10-Q · filed 2025-02-14 | $701.87K derived: sum of 2 quarters · filed 2025-02-14 | $701.87K derived: sum of 3 quarters · filed 2025-02-14 | |
| 2023-09-30 | $581.04K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-13 | $581.04K derived: sum of 2 quarters · filed 2024-12-13 | $581.04K 10-K · filed 2024-12-13 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |